WebbPLN-74809, is an oral once daily antifibrotic being studied for the treatment of idiopathic pulmonary fibrosis (IPF). PLN-74809 inhibits integrins αVβ1 and αVβ6, which in turn blocks activation of TGF-β, a central mediator of fibrosis. This upstream inhibition of TGF-β activation may prevent the formation of fibrotic tissue within the lung. Webb3 juni 2024 · Idiopathic pulmonary fibrosis (IPF) is a serious chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs. The median survival of IPF …

Pliant Therapeutics to Participate in the 22nd Annual

WebbPLN-74809: Pliant Therapeutics PLN-74809: Pliant TherapeuticsLN-74809 is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Webb22 jan. 2024 · Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, bexotegrast ... foucher pro tip top

Pliant

WebbPliant is evaluating PLN-74809 in fibrotic diseases with unmet clinical needs, including primary sclerosing cholangitis, a chronic progressive disorder characterized by inflammation and fibrosis of the bile ducts in the liver, and idiopathic pulmonary fibrosis. “Pliant’s preclinical research in sophisticated translational models using human ... Webb6 apr. 2024 · Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic … Webb19 okt. 2024 · Precision-cut lung slices generated from lung explants from patients with idiopathic pulmonary fibrosis or bleomycin-challenged mouse lungs were treated with integrin inhibitors or standard-of-care drugs (nintedanib or pirfenidone) and analyzed for changes in fibrotic gene expression or TGF-β signaling. disabled woman with mold growing on her body